HeartWare HVAD for the Treatment of Patients With Advanced Heart Failure Ineligible for Cardiac Transplantation: Results of the ENDURANCE Destination Therapy Trial
Francis D. Pagani(Michigan Medicine), Joseph G. Rogers(Baylor College of Medicine), Emma J. Birks(Lung Institute), Katrin Leadley(Heartware International (United States)), Steven W. Boyce(George Washington University Hospital), Valluvan Jeevanandam(University of Chicago), Antone Tatooles(Rush University Medical Center), Igor D. Gregorič(The University of Texas Health Science Center), Carmelo A. Milano(Duke University Hospital), Keith D. Aaronson(University of Michigan), Reynolds M. Delgado, Samer S. Najjar(University of Tennessee Health Science Center), Allen S. Anderson(Northwestern University), Geetha Bhat(Christ Hospital), Mark S. Slaughter(University of Louisville)
Cited by 61
Related Papers
Elevated Aortic Pulse Wave Velocity, a Marker of Arterial Stiffness, Predicts Cardiovascular Events in Well-Functioning Older Adults
|Circulation|2005|1.2k
Genome-wide association study identifies eight loci associated with blood pressure
|Nature Genetics|2009|1.2k
Clinical management of continuous-flow left ventricular assist devices in advanced heart failure
|The Journal of Heart and Lung Transplantation|2010|876
Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure
|New England Journal of Medicine|2017|757
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke
|New England Journal of Medicine|2021|711